Stay updated on Magrolimab vs. Venetoclax in TP53 AML Clinical Trial

Sign up to get notified when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    - Revision: v3.3.4 updated (replacing v3.3.3). The overall study information on the page remains unchanged.
    Difference
    0.0%
    Check dated 2026-01-15T04:19:08.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    29 days ago
    Change Detected
    Summary
    Added a Locations section with a comprehensive list of study sites across the US and Australia; previous location entries were removed.
    Difference
    1%
    Check dated 2025-12-24T16:28:13.000Z thumbnail image
  5. Check
    58 days ago
    Change Detected
    Summary
    Publications note updated to say PubMed publications are automatically filled from PubMed, and the revision tag changed from v3.2.0 to v3.3.2.
    Difference
    0.0%
    Check dated 2025-11-25T14:51:55.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    The page no longer displays the government-funding operating-status notice; core study information such as the title, eligibility, and locations remains unchanged.
    Difference
    0.1%
    Check dated 2025-11-18T07:35:29.000Z thumbnail image
  7. Check
    87 days ago
    Change Detected
    Summary
    No significant changes detected in the Study Details for NCT04778397; core information such as the study design, eligibility criteria, and primary outcomes remains unchanged.
    Difference
    0.2%
    Check dated 2025-10-27T21:11:58.000Z thumbnail image
  8. Check
    109 days ago
    Change Detected
    Summary
    Additions introduce a current operating-status notice and a version upgrade (v3.2.0); deletions remove the previous version tag (v3.1.0). The page now communicates potential delays due to funding and points to official sources for updates.
    Difference
    2%
    Check dated 2025-10-06T08:56:20.000Z thumbnail image

Stay in the know with updates to Magrolimab vs. Venetoclax in TP53 AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Magrolimab vs. Venetoclax in TP53 AML Clinical Trial page.